VelosBio: Exclusive: Decheng's Inside View of Merck's $2.75 Billion Acquisition of VelosBio

Decheng Capital had good reason to be pleased when Merck paid $2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer. In an exclusive interview, Min Cui, PhD, Founder and Managing Director of Decheng, told ChinaBio® Today, "We are VelosBio's largest shareholder because we backed the company from day one. It's a huge win for us and all the stakeholders, including Merck and cancer patients. We were the original firm who led VelosBio's seed funding and participated in the A round and the recent $137 million B funding. We were ready to IPO, but Merck decided they wanted to own the company." More details.... Stock Symbol: (NYSE: MRK) Share this with colleagues: